C4 Therapeutics, Inc. (CCCC)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Andrew J. Hirsch M.B.A.
|
CEO, President & Director | 1.38M | -- | 1971 |
|
Dr. Kenneth C. Anderson M.D., Ph.D.
|
Co-Founder, Independent Director & Member of Scientific Advisory Board | 45.75k | -- | 1951 |
|
Ms. Kendra R. Adams
|
Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | 869.51k | -- | 1977 |
|
Dr. Leonard M. J. Reyno M.D.
|
Chief Medical Officer | 1.03M | -- | 1962 |
|
Dr. Nathanael S. Gray Ph.D.
|
Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
|
Ms. Courtney Solberg
|
Senior Manager of Investor Relations | -- | -- | -- |
|
Ms. Kelly A. Schick
|
Chief People Officer | -- | -- | 1980 |
|
Dr. Isabel Chiu Ph.D.
|
Senior Vice President of Strategic Alliances & Business Development | -- | -- | -- |
|
Dr. Christopher Nasveschuk
|
Senior Vice President of Chemistry | -- | -- | -- |
|
Mr. Roy Pollock Ph.D.
|
Senior Vice President of Biological Sciences | -- | -- | -- |
C4 Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 104
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
C4 Therapeutics, Inc. Earnings Date
